stock price decline

Law firm investigates Stellantis for potential securities violations after €22.2 billion charge announcement triggers 23.7% stock plunge to $7.28.

Aquestive Therapeutics faces securities fraud lawsuit after FDA rejected Anaphylm drug, contradicting management's prior "on track" statements; $AQST stock fell 37%.

$DRVN plunged nearly 40% after disclosing accounting errors and control weaknesses requiring multi-year restatement. Securities fraud lawsuit filed with May 8 deadline.

Alight Inc. faces securities fraud lawsuit after missing guidance twice, with stock falling 18-38%. Shareholders can claim losses through May 2026.

Portnoy Law Firm investigates Upstart Holdings for securities fraud following November 5 disclosure that its Model 22 underwriting system underperformed, causing sharp stock decline and investor losses.

Soleno Therapeutics faces class action lawsuit over alleged failure to disclose safety issues with drug DCCR, following 12-27% stock declines from August-September 2025 revelations.

Law firm investigates $TBRG for potential securities violations after revealing out-of-period accounting errors spanning 2023-2025. Stock fell 10.5%.

Law firm files class action against $TCOM for alleged securities fraud related to concealed antitrust investigation. Stock plunged 17% after disclosure.

Bragar Eagel & Squire investigates Arq Inc. ($ARQ) after 49% stock collapse following missed earnings, weak guidance, and unexpected production halt.

Three Super Micro Computer executives indicted for export violations; stock plummets 33%. Law firm investigates potential securities fraud claims.

Law firm investigates $STLA for potential securities violations following €22.2B charge announcement that crashed stock 23.7% in single day.

Class action lawsuit filed against $ODD alleging material misstatements about advertising partner algorithm changes that devastated customer acquisition costs and Q1 revenue.

Robbins LLP files class action against Gartner for allegedly misrepresenting growth projections. Stock fell 21% after company disclosed weaker-than-expected contract value growth.

Law firm investigates $GDDY after Q4 earnings miss. Stock fell 14% on disappointing bookings, .com domain pricing pressure, and cautious 2026 outlook.

Kyndryl faces securities fraud lawsuit after CFO departure, SEC investigation into cash practices, and inability to file quarterly reports. Stock plummeted 54.9%.

ODDITY Tech stock crashed 49.2% after disclosing algorithm changes from major ad partner will slash Q1 2026 revenue by 30%. Securities fraud investigation underway.

Kessler Topaz files class action against $QURE over alleged misleading statements about AMT-130 FDA approval timeline, following 49% stock plunge in November 2025.

Fulgent Genetics shares crashed 38% after cutting 2026 guidance due to largest customer shifting work in-house. Law firm investigating potential securities violations.

Law firm Kirby McInerney reminds Paysafe investors of April 7, 2026 deadline to join securities class action over alleged disclosure failures that triggered 27.6% stock decline.

Corcept Therapeutics faces class action lawsuit for allegedly misrepresenting FDA trial data; stock collapsed 50% after regulatory rejection of relacorilant drug.